• Coyuchi Inc. is a California-based bed and bath lifestyle brand focused on sustainable practices and producing comfortable, organic products
• The company had a net income of $1.4 million on sales of $33 million last year
• Coyuchi is expanding its product line with two new items sourced from cotton that the company helped grow as part of a collaborative, soil-rejuvenating project last year
• The company launched a Reg A+ investment offering last year and announced that capital raised had topped $1 million by the end of the year
• In a recent podcast interview, the company’s CEO and president outlined Coyuchi’s priorities for expanding its brand in the coming months

Luxury bed, bath and apparel organic product innovator Coyuchi has built its market appeal on a vision of furnishing homes with earth-sustaining, comfortable products for everyday living while keeping its brand similarly fresh as its profile evolves.

“When Coyuchi was founded 30 years ago, the original founder — her goal was to bring organic cotton into the textile industry for home goods, and we’ve really taken that mission to heart and are finding ways to expand on it and continuing to look at the whole process of what we do,” company President and CEO Eileen Mockus said during a recent podcast interview.

“There’s no hall pass for sustainable products. We want what we want, and from my standpoint that’s the most comfortable sheets that you can sleep on, the amazing towel when you get out of the shower that’s absorbent and soft next to your skin,” Mockus told Bell2Bell host Stuart Smith (https://ibn.fm/SpXVN). “Those are the things that we want to incorporate into what you’re buying into when you buy from Coyuchi and, of course, as you invest in Coyuchi.”

All Coyuchi products are created with 100 percent organic fibers and the company demonstrates its commitment to climate-conscious consumers with a traceable supply chain. Coyuchi’s vision includes a production side that will achieve net zero emissions within the next two to three years and net positive emissions by 2030 as part of its earth stewardship mission.

Mockus noted that for two new products that will launch this year, Coyuchi used cotton derived from a collaborative cultivation project on a California farm, using renewable agricultural practices in tandem with the company’s partners in a group called the California Cotton and Climate Coalition (known as C4).

The success of the company’s vision can be seen in some of the customer reviews posted with department store chain Nordstrom’s online site, which has become part of Coyuchi’s supply chain.

“Perfect weight for summer,” one customer wrote about a purpose-crinkled Organic Cotton Percale Sheet set (https://ibn.fm/nvAAu). “these cotton sheets are incredible. I used to only buy high thread count sheets, and even (though) these are not high TC they are amazing with every wash. I live in Fla so used them year round, with layers as needed. Would def be great for summertime in any part of the country.Generally I love this brand and feel good about buying their products. They are mindful about packaging and sustainability… I wish more manufacturers paid mind in these regards.”

Coyuchi is expanding its partnerships with department store retailers, Mockus said.

“We’ll have more of this coming in 2023,” she said. “We’re really interested in partnerships with other retailers. Seventy percent of bedding purchases are made through department stores. We’re an online business and we want to show up with other retailers.”

Investors are welcomed to join with the company’s vision through its Reg A+ offering launched last year, which topped $1 million in capital flow by the end of last year.

“The company is profitable and growing. For the year ended Dec. 31, 2021, the company had net income of $1.4 million on sales of $33 million,” Smith noted.

For more information, visit the company’s website at www.Coyuchi.com.

NOTE TO INVESTORS: The latest news and updates relating to Coyuchi are available in the company’s newsroom at https://ibn.fm/COYU

• A new report projects that the global direct-selling establishments market size will grow from $688.45 billion in 2022 to $763.85 billion in 2023
• SHRG is focused on positioning itself to take advantage of projected growth
• The company has developed opportunities in several spaces, including the health and wellness, travel, and restaurant sectors

In a market forecast to see almost $80 billion growth (https://ibn.fm/7ZJfu), Sharing Services Global (OTCQB: SHRG) is working to offer a variety of options for its brand partners, subscribers and independent sales force. SHRG operates in the direct-selling space, where it is dedicated to developing or acquiring businesses, products and technologies that augment its product and services portfolio and create opportunities for those involved with the company.

“The global direct-selling establishments market size will grow from $688.45 billion in 2022 to $763.85 billion in 2023 at a compound annual growth rate (‘CAGR’) of 11%,” reported the Business Research Company. “The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short-term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global direct-selling establishment’s market size is expected to grow to $1,125.52 billion in 2027 at a CAGR of 10.2%.”

SHRG is focused on positioning itself to take advantage of the growth the sector is projected to experience. The company has developed opportunities in several spaces, including the health and wellness, travel, and restaurant sectors (https://ibn.fm/ExU5C).

As a wholly owned SHRG subsidiary, the Happy Co. operates in the health and wellness industry. The company’s products are marketed primarily through an independent sales force following a direct-selling business model. Currently, the Happy Co. markets and distributes its products in the United States. In addition, the company sells its health and wellness products on a “not-for-resale” basis to consumers in countries outside the U.S.

My Travel Ventures is also a wholly owned subsidiary. As a subscription-based company, My Travel Ventures delivers subscription-based travel services designed to offer the deepest discounts for travel related to airfare, cruises, hotels, resorts, time shares and rental cars. The services are geared for destinations throughout the world and for people of all ages, demographics and economic backgrounds. My Travel Ventures also provides entrepreneurial opportunities to its subscribers by capitalizing on both the direct-selling model and the retail travel business model.

Finally, Sharing Services has entered into an agreement to acquire the exclusive franchise rights in North America to the Hapi Café(TM) brand from Hapi Café Inc. Under the agreement, SHRG will operate directly or through its subsidiaries at least five corporate-owned stores and will also offer licensing rights for others to operate. Each corporate-owned or licensed Hapi Café location will provide customers and brand partners seeking a healthier lifestyle access to functional, healthy food and beverages, a pleasant workspace with free WiFi service, physical fitness, nutrition management, personal workout video content and My Travel Ventures services.

Sharing Services is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. In addition to its interest in the opportunities mentioned above, the company currently has a controlling interest in MojiLife, which offers a flagship product to scent homes and vehicles that features innovative technology and design (https://ibn.fm/gw2Ko).

For more information, visit the company’s websites at www.SHRGInc.com, www.MyTravelventures.com and www.TheHappyCo.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• In addition to a recently released shareholder update letter from the company’s CEO, Chris Bunka, Lexaria Bioscience has now released a new investor presentation
• Despite 2022 inflationary conditions, Lexaria has seen growth company-wide – including hitting annual budgets +/- 2% over the last two years
• Lexaria’s patented DehydraTECH(TM) technology offers more effective delivery of active pharmaceutical ingredients into the bloodstream and brain tissue with 28 patents granted and roughly 50 patent applications pending worldwide
• For Q1 2023, Lexaria expects additional results from its hypertension study HYPER-H21-4, dosing completion in its animal dementia study and diabetes study, dosing completion in human nicotine study NIC-H21-1, and submissions and publishing of additional results in research journals
• Lexaria’s anticipated mid-year IND filing would be an important milestone for the company, providing additional interaction with the pharmaceutical industry

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has released its new corporate presentation (https://ir.lexariabioscience.com/presentations). The presentation augments the positive outlook for the coming year put forth in an earlier released shareholder update letter from the company’s CEO, Chris Bunka.

Bunka starts the letter with, “As 2022 came to a close, it isn’t news that nearly all companies – not to mention most people – are facing challenges not experienced in years. Lexaria continues to navigate well and is focused on those things it can control, such as applied R&D designed to entice others to work with us commercially.”

The letter (https://ibn.fm/Yn6uH) shares that despite the some challenging conditions of 2022, Lexaria is forging ahead. It has not terminated staff but is experiencing the opposite, growing its external headcount to numbers higher than it has been in the past. This has allowed the company to conduct and analyze an unprecedented volume of work. Lexaria has managed to grow while exercising excellent fiscal controls, hitting annual budgets +/- 2% for the last two years. Lexaria plans for further growth in 2023 with its patented DehydraTECH(TM) technology.

DehydraTECH is a disruptive drug delivery technology that is more effective at delivering active pharmaceutical ingredients (“APIs”) into the bloodstream and brain tissue. It is applied to multiple ingestible product formats, including tablets, capsules, oral suspensions, mouth melts, and more.

The company has already seen 28 patents granted and roughly 50 patent applications pending worldwide for its DehydraTECH technology (https://ibn.fm/TB2sL). Pharmacokinetic studies have shown the delivery of higher API quantities in less time, including cannabidiol (“CBD”) for hypertension, oral nicotine for reduced risk, and antiviral drugs for COVID-19 and other infectious diseases. An Investigational New Drug (“IND”) enabling program is currently underway for DehydraTECH-CBD as a prospective registered treatment for hypertension with the U.S. Food and Drug Administration (“FDA”).

Pushing forward in 2023, Lexaria’s DehydraTECH drug delivery platform has multiple mainstream applications in cannabinoids, oral nicotine, antivirals, phosphodiesterase inhibitors, and other APIs. This technology increases bioavailability, improves the speed of onset, reduces drug administration costs, and masks unwanted tastes. The company’s pipeline addresses serious unmet patient needs with substantial market potential.

For Q1 2023, Lexaria expects additional results from its hypertension study HYPER-H21-4, dosing completion in its animal dementia study and diabetes study, dosing completion in human nicotine study NIC-H21-1, and submissions and publishing of additional results in research journals. Additionally, during 2023, Lexaria expects to both submit its IND file and commence its IND clinical study – a major step in its maturation as a pharmaceutical company and will be the primary research focus once it begins.

Lexaria believes that if the IND hypertension program is a success, it could potentially pave the way for more commercial pursuits of DehydraTECH-CBD for therapeutic use. This would be a real milestone for the company as an additional way to interact with the pharmaceutical industry.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT(R), a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT(R) to the U.S. FDA. proBEAT(TM) combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT(R) diabetes program that is currently undergoing pilot studies.

Additionally, Nemaura has launched Miboko, a new metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

The company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

To join the 3rd Annual Winter Wonderland Best Ideas Investor Conference, visit https://microcaprodeo.com

About InvestorBrandNetwork’s Virtual Coverage

The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, provides the online investment community with custom-built portals that include summaries on hundreds of presenting companies. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN utilizes social media and syndicated articles to maximize the visibility of various investor conferences.

For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

• The modern workplace has undergone a radical shift in recent years, moving increasingly away from an office-centric model towards a more hybrid working environment
• Corporate employees are revealing they are increasingly spending more time in meetings, with over 77% of these taking place online
• Users can host and attend meetings in lifelike virtual reality – with no software downloads – engaging their audiences in a more collaborative and fun way
• In April 2022, the company launched the world’s first web-based, mobile-friendly, audio and video conference platform

Early on Tuesday 8th January 2019, WeWork announced that the company had successfully concluded a $6 billion funding round; the funding exercise – which would ultimately result in the single largest capital raise for a start-up in modern corporate history, valued WeWork at $47 billion on that occasion. At the time, WeWork was heralded as the ultimate disruptor, with Softbank CEO, Masayoshi Son branding the company as possessing a “technology platform that provides a complete solution for space needs” (https://ibn.fm/4bh4D). In-person work was thriving and WeWork had expanded ferociously, broadening its presence to over 425 sites across 27 countries in the nine years since its founding. Less than 14 months later, WeWork’s founder would be ignominiously ousted with the company’s market capitalization written down to a relatively measly $2.9 billion by its lead investor. Whilst WeWork may have symbolized the future of work at its peak in 2019, the global corporate reality in 2023 paints a starkly different picture. A recent study found that on average, professionals were spending over half of their 40-hour workweek in meetings, with 77% of that time spent in an online, videoconferencing environment (https://ibn.fm/ha7Lj) rather than engaging in an in-person meeting as was envisioned only a few years earlier. With employees the world over radically changing their work practices post the recent pandemic, companies are striving to cater to the dramatic shift in corporate and consumer needs; few however have been as impactful as Utopia VR.

Utopia VR is a diversified technology company, pioneering the concept of the ‘Metaverse-As-A-Service’, while centering its focus on the provision of virtual experiences for both businesses and consumer audiences. Launched in April 2022, Utopia VR’s metaverse solution has emerged as the world’s first web-based, mobile-friendly, audio and video conference platform utilizing innovative, 3D, web technology. Users on the platform are enabled to hold Zoom-like, virtual meetings in 3D, or experience those same meetings in lifelike Virtual Reality. Moreover, and uniquely amongst peers, Utopia VR’s metaverse operates across all devices – PC, mobile and virtual reality headsets – whereas many competitors only work in VR or on PC.

When Facebook founder Mark Zuckerberg posted an online image of his very own metaverse-based avatar in mid-2022, he was potentially spelling out the future of the office – a workplace wherein research house, Gartner believes that the metaverse’s “potential to change how individuals and organizations interact with one another and the world around them is so enormous that technology product and service providers already need a strategy” (https://ibn.fm/tZKIY).

In fact, and to that end, data consolidator Statista recently estimated that the global metaverse market size stood at $38.85 billion in 2021, projecting that the industry could soon explode to reach $678.8 billion by 2030, achieving a CAGR of more than 39% over the period. In an even more optimistic scenario, consultancy McKinsey & Company recently forecast that the metaverse could create $5 trillion in opportunity within the same interim of time (https://ibn.fm/pUFOB).

Considering this, Utopia VR’s strategy is clear. The company has sought to revolutionize the work place as we know it, focusing their business model on disrupting the future of enterprise, education and corporate remote solutions. With a management team boasting extensive experience within both, technology and financial markets, an innovative and live product platform and having already started generating revenues, Utopia VR looks well placed to capitalize and pioneer the implementation of the metaverse in the workplace. And unlike Mark Zuckerberg’s initial avatar, the company’s business model seems to have a leg to stand on.

For more information, visit the company’s website at www.UtopiaVR.com.

NOTE TO INVESTORS: The latest news and updates relating to Utopia VR are available in the company’s newsroom at https://ibn.fm/Utopia

• Cannabis businesses continue to face challenges finding opportunities for financing despite the continued drive for legalization
• REZYFi is pivotal providing much-needed support to the cannabis industry through two wholly owned subsidiaries – REZYFi Lending and ResMac Inc.
• For 2023, combined cannabis industry sales are projected to reach $38.8 billion

In recent years, the cannabis industry has seen significant changes – with 39 states legalizing cannabis for medicinal use and 21 states allowing recreational use. For 2023, the combined sales are projected to reach $38.8 billion for the industry (https://ibn.fm/dqo2m). In spite of this significant growth, there is a challenge that cannabis businesses face – access to loans, deposits, and credit cards. Even with Congress’ repeated attempts to pass banking and tax reform for the cannabis industry, there has not been a legislative consensus or enough political will to get it done.

Positioned as one of the first cannabis mortgage bankers in the United States, REZYFi is servicing the needs of both traditional and non-traditional consumers and businesses. The company targets markets that include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings. Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending and ResMac Inc.

Through REZYFi Lending, the company leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans, and adjustable-rate mortgages. REZYFi expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, supported by its planned launch of a high-margin cannabis division.

REZYFi’s second wholly-owned subsidiary, ResMac, has been operating for 13 years. It has closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals. The global overall loan servicing market size was valued at $680.8 million in 2021. By 2028, the market is expected to reach $1426.6 million, growing at a CAGR of 11%, growth driven by a rise in demand for offering increased financing for mortgage lenders (https://ibn.fm/VHIQg).

Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers and believes that this network will be a vital asset moving forward. Using its corporate strengths, REZYFi plans to expand its offering to all states and is currently licensed in 36 states. REZYFi plans to use its seasoned management team, which includes extensive experience in the cannabis and hemp marketplace.

For more information, visit the company’s website at www.REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• Ucore’s RapidSX(TM) Demonstration Plant will be located within the company’s 5000 square foot Commercialization and Demonstration Facility in Kingston, Ontario
• A Strategic Metals Complex is being planned in Louisiana with an initial capacity of 2,000 tonnes per annum and increasing to production of 5,000 tonnes
• Cerium, neodymium, lanthanum, praseodymium, yttrium, and dysprosium are expected to remain the most sought-after REEs, with high demands in magnet manufacturing and the automobile industry
• The global rare earth element market was valued at $2.8 billion in 2018 and is expected to grow at a CAGR of 10.4% through 2025

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a company focused on Rare Earth Element (“REE”) resource development and precious metal commercialization, recently provided an update on the commissioning process for its RapidSX(TM) Demonstration Plant for the separation of heavy and light REEs. The demonstration plant is located within Ucore’s 5000 square foot RapidSX(TM) Commercialization and Demonstration Facility in Kingston, Ontario, and is run by its research development partner, Kingston Process Metallurgy Inc. (https://ibn.fm/qkkf8).

Ucore’s vision includes becoming a leading advanced technology company that provides the best-in-class metal separation products and services to the mining and mineral extraction industry. The company also plans to aid in developing the North American REE supply chain controlled by the U.S. and its allies through strategic partnerships.

Innovation Metals Corp., which was acquired by Ucore in 2020, developed the RapidSX(TM) technology – with early-stage assistance from the United States Department of Defense. This has resulted in the production of commercial-grade, separated REE at the pilot scale. Utilizing chemistry similar to traditional solvent-extraction (“SX”) technology, RapidSX(TM) is not “new” technology but rather a significant improvement on well-established, well-understood, and proven conventional separation technology preferred by leading REE producers.

The global REE market was valued at $2.8 billion in 2018 and is expected to grow at a CAGR of 10.4% through 2025, with cerium, neodymium, lanthanum, praseodymium, yttrium, and dysprosium likely to remain the most commonly sought-after REEs. These REEs are expected to drive the market’s growth due to the increased demand for use in products in magnet manufacturing and catalysts for the automotive industry (https://ibn.fm/43P58).

With the commissioning of Ucore’s demonstration plant, the company plans for the output of products that are high-purity NdPr, praseodymium, neodymium, terbium, and dysprosium REEs, to be incorporated into the early stages of original equipment manufacturers’ OEM qualification trials. The company is also working closely with partners to develop the full-scale engineering for the company’s first Strategic Metals Complex, with construction commencing in Louisiana this year. It is scheduled to have an initial capacity of 2,000 tonnes per annum of total rare earth oxides, increasing to 5,000 tonnes in 2026.

“We are extremely pleased with the work at the CDF in concert with our partners, KPM, Mech-Chem, and a host of other supporting contractors and vendors. As we work toward near-term commercial deployment of the RapidSX™ rare earth element separation technology in North America,” said Ucore’s VP and COO, Mike Schrider, P.E. “Implementing the Demo Plant commissioning process is a huge milestone for the team, and this is scheduled to be followed by a series of heavy and light rare earth element process demonstrations separating tens of tonnes of mixed rare earth concentrates over thousands of hours of facility run-time.”

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Market analysts predict monoclonal antibodies (“mAbs”) will be the fastest-growing revenue segment of the biologics medicinal market through the end of the decade
• BiondVax Pharmaceuticals is focused on developing and commercializing novel mAb “biobetter” NanoAbs to meet underserved medical needs addressing large market disorders
• The company’s recent work with an inhaled nanosized antibody for COVID has shown exceptionally promising results, virtually preventing illness and eliminating the SARS-COV-2 virus in a hamster population
• With COVID as first target, the company’s pipeline aims to provide effective medical responses to other disorders such asthma, psoriasis, psoriatic arthritis, and macular degeneration

Immunotherapeutic product innovator BiondVax Pharmaceuticals (NASDAQ: BVXV) is focused on developing, manufacturing, and commercializing innovative nanosized antibodies (NanoAbs) for the treatment of infectious diseases and autoimmune diseases, stepping up its pursuit of disrupting the monoclonal antibody (“mAb”) market amid forecasts that the global mAb market will grow at a compound annual rate (“CAGR”) of 11.30 percent through 2030.

Grand View Research analysts reported recently that the global mAbs market size at the end of 2021 was valued at $185.50 billion and $210.06 billion by the end of 2022, with expectations it will reach $494.53 billion in revenues during the next eight years (https://ibn.fm/ki8n5).

BiondVax’s recent work with innovative “biobetter” NanoAb therapies in diseases underserved by current mAb treatments has led to exceptionally promising results from a preclinical proof-of-concept study of its inhaled COVID-19 therapy, in which it virtually eliminated SARS-COV-2 virus in the lungs, and led to significantly shorter and milder illness, according to the company (https://ibn.fm/s598q). Additional results of the preclinical study also showed promising prophylactic results with the potential to provide proactive protection for at risk patients.

“We continue to be thrilled with the results of this ongoing trial,” stated Amir Reichman, BiondVax’s CEO. (https://ibn.fm/q7ltP). “There is strong market demand for COVID prophylactics as evidenced by AstraZeneca’s reported Q1 through Q3 2022 EVUSHELD revenues of $1.5 billion. EVUSHELD is currently the only prophylactic COVID medication with FDA approval, under emergency use authorization. Our inhaled NanoAb is designed to be self-administered at the time of choosing to generate rapid protection from COVID illness. In contrast, EVUSHELD must be administered via two separate consecutive intramuscular (‘IM’) injections in a health care setting… we believe the additional ‘biobetter’ value provided by our NanoAb potentially positions it to capture significant market share both for treatment and prevention of COVID illness.”

Its important to note that recent data show EVUSHELD is unlikely to be active against certain SARS-CoV-2 variants and as of January 26, 2023, EVUSHELD is no longer authorized by the FDA for use in the U.S. (https://ibn.fm/fCEc6). AstraZeneca reported that EVUSHELD had generated $1.451 billion in revenue from Q1 through Q3 2022 (https://ibn.fm/bBAGS). BiondVax aims to fill the growing void in COVID prophylactics and therapeutics.

BiondVax’s pipeline of NanoAbs is expected to provide biologics that interact with previously validated therapeutic targets and have strong potential for significant advantages over currently approved human mAbs.

“NanoAbs being generated at MPI demonstrate several unique attributes such as greater binding affinity, stability at high temperatures, and formulation advantages,” Reichman stated. “We believe that if NanoAbs with these attributes can be successfully developed they would provide an opportunity to capture a meaningful share of several large and growing markets while reducing upfront costs and risks commonly associated with new drug development (e.g., biological target validation) and accelerating initiation of clinical development.”

There’s and old adage that ‘good things come in small packages’ and indications are that BiondVax’s NanoAbs may soon prove the adage true.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• Lexaria has developed the DehydraTECH drug delivery technology, which enhances the performance of multiple categories of fat-soluble active molecules and drugs
• DehydraTECH has been shown to increase intestinal bioabsorption of certain bioactive compounds by as much as 27 times, with its onset of action being as little as 1.5 minutes
• The technology is also expected to lower the overall drug costs because it delivers more active molecules to the blood plasma and brain, thus necessitating lower dosing, all while resulting in cost-effective manufacturing
• DehydraTECH is protected by 28 patents granted worldwide, with approximately 50 more pending

Speaking during a late 2022 interview (https://ibn.fm/cWQJX), Chris Bunka, the Chairman and CEO of Lexaria Bioscience (NASDAQ: LEXX), emphasized the varied applications of DehydraTECH(TM), and that, for example, the company intends to help people quit smoking by enabling them to satisfy their nicotine cravings in a way that will not kill them: pouches. This comes against a backdrop of worrying statistics, which show that over 480,000 people in the United States (https://ibn.fm/mE4f3) and over 8 million people globally (https://ibn.fm/lSxYa) die annually from cigarette smoking.

Lexaria also sees an opportunity to help people with hypertension, which affects about 116 million people in the US (https://ibn.fm/cqKRT) and seizure disorders, which affect 3.4 million people in the US and 65 million globally (https://ibn.fm/v87fO). “We really do believe Lexaria is going to make the world a better place,” Bunka emphasized in closing.

The company’s belief in a better tomorrow is anchored in its patented DehydraTECH technology, which enhances the performance of multiple categories of fat-soluble active molecules and drugs available in various formats, including oral ingestible, oral buccal/sublingual, and topical products. According to Lexaria, its technology “is best thought of as an additional layer that improves the effectiveness of existing or planned new products for companies that offer consumer supplements, prescription and non-prescription-based drugs, and nicotine products” (https://ibn.fm/RuNmo).

When analyzed in terms of numbers, the improvements are impressive. Having conducted both in vitro and in vivo studies, Lexaria has established that DehydraTECH increases intestinal bioabsorption of certain bioactive compounds by as much as 27 times. Furthermore, given the technology increases the quantity of each active ingredient delivered to the blood plasma and brain, it reduces the need for high doses, ultimately contributing to lower overall drug costs as lower doses can still achieve the same or even better results.

In addition, the technology works rapidly, with the DehydraTECH formulations’ effects becoming prominent in as little as 1.5 minutes post-administration. Other benefits include masked taste and smell of the active molecules, which has the intended effect of helping manufacturers create low-sugar products with fewer calories and avoid using artificial sweeteners.

Manufacturers can also register other benefits, especially considering the process is very cost-effective, according to the company. “Micro quantities of fatty acids (Generally Recognized as Safe, or GRAS, ingredients) are incorporated into drugs, consumer packaged goods, and capsule products at a fraction of a penny per serving,” the company’s website reads. “DehydraTECH technology works with process equipment readily found in most commercial kitchen/production facilities, is easily utilized under GMP certification as needed, and is highly scalable.”

The technology, which is protected by a robust suite of 28 patents granted worldwide (https://ibn.fm/fOmIF), has so far been used to enhance the capabilities of cannabidiol (“CBD”), nicotine, antivirals, and PDE5 inhibitors, to mention a few, with pharmacokinetic studies evaluating the resultant formulations showing positive results.

The recently completed HYPER-H21-4 study, for instance, which evaluated DehydraTECH-CBD as a potential treatment against hypertension, showed that the formulation resulted in statistically significant lowering of 24-hour ambulatory blood pressure as well as sustained blood pressure reduction (https://ibn.fm/64eAI). HYPER-H21-3 showed attenuated pulmonary artery systolic pressure (https://ibn.fm/CY8CH), while HYPER-H21-2 evidenced up to a 23% reduction in overnight blood pressure and reduced arterial stiffness (https://ibn.fm/k3usL). Lexaria is currently preparing the paperwork needed to file an Investigational New Drug (“IND”) application with the Food and Drug Administration (“FDA”) as a precursor to commencing registered clinical trials.

Separately, in an animal study, Lexaria showed that DehydraTECH-nicotine delivered through the mucous membrane in the mouth resulted in a 10-20x reduction in time to deliver peak levels of nicotine to the bloodstream and 2-3x higher levels of nicotine in the blood (https://ibn.fm/YIJ9V). In yet another animal study comparing DehydraTECH-CBD to Epidiolex(R), the first and only FDA-approved CBD medication for the treatment of seizures, Lexaria observed that its formulation appeared to demonstrate effectiveness at lower doses and more rapidly than Epidiolex (https://ibn.fm/Zhg3G).

By targeting conditions and spaces that affect millions of lives, Lexaria is indeed working to make the world a better place, alleviating the suffering of scores of people.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• 30-year fixed-rate mortgages with conforming loan balances of $726,200 or less, saw rates decrease from 6.42% to 6.23% for the week ending January 18, 2023, resulting in a 28% increase in mortgage application volume, and a 34% increase in refinance demand
• It is projected that by the end of 2023, mortgage rates in the country will drop by 5.25%, coming from 2022, which saw home financing costs nearly double
• These rate drops present an opportunity for REZYFi to grow its customer reach, market share, and revenue but also offer an avenue for the growth of the housing finance sector

REZYFi, a growth mortgage origination and specialized financing company based in the United States is set to see a growth in the demand for its services in response to the changing financing market that has seen a drop in interest rates in the past few weeks. January 18, 2023, saw mortgage rates hit the lowest level since September 2022, and the market reacting with an increased demand for mortgages (https://ibn.fm/MPApD).

Rates decreased from 6.42% to 6.23% for the average 30-year fixed-rate mortgages with conforming loan balances of $726,200 or less. In turn, mortgage application volume grew by nearly 28%, while refinance demand increased by 34% on the week ending January 21 compared to the previous week. In addition, it is projected that as more homes are listed on the market, the rates could go even lower, resulting in a further increase in mortgage demand.

“As we enter the beginning of the spring season, lower mortgage rates and more homes on the market will help affordability for first-time homebuyers,” noted Mike Fratantoni, MBA’s senior vice president and chief economist.

As a company that offers origination, structures, and investments in first mortgage loans and alternative structured financings secured by commercial real estate properties, the recent developments are much welcome. Of note is the anticipated sustained increase in the additional demand for mortgages, particularly given that 2022 saw home financing costs nearly double. Furthermore, it is projected that by the end of the 2023 calendar year, mortgage rates in the United States will drop to 5.25%, according to Bankrate (https://ibn.fm/mLGFE). While it will not be anything like pre-pandemic lows, it would still be significant in making real estate ownership more accessible and affordable, which is something REZYFi is looking to achieve.

The growing acceptance of cannabis-derived products and the support the industry has received so far are an opportunity for REZYFi and an avenue for the growth of the finance sector. The conversation surrounding the products and the companies that deal with cannabis has helped advance policy, creating an opportunity for companies such as REZYFi, and presenting customers with options. The dropping mortgage rates reflect an industry that is responding to the times. With this comes an even more significant opportunity for REZYFi to increase its customer reach, market share, and revenue.

Already, the company is positioning itself to cater to its target market and the challenges associated with lending to companies and individuals within the cannabis space. With the anticipated launch of its high-margin cannabis division and the development of proprietary technology, REZYFi is stamping its position as a market leader. But, more importantly, it is reaping the rewards of an industry that is slowly improving in performance and proving more accommodating, albeit slowly, to stakeholders in the cannabis space.

For more information, visit the company’s website at www.REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY